Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.34 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29570896 | 0.86 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL2264568 | 0.86 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL19158572 | 0.83 | MEN1 (0.49) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL11846170 | 0.80 | MEN1 (0.46) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL1573628 | 0.79 | CYP2D6 (0.45) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL17120414 | 0.79 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL26201345 | 0.79 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL17121746 | 0.79 | MEN1 (0.51) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL11840965 | 0.78 | CYP2D6 (0.44) | MEN1CYP3A4CYP2D6KMT2AHTR2A | |
| SCHEMBL9544082 | 0.77 | MEN1 (0.50) | MEN1CYP3A4CYP2D6KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912397-A | Gefitinib intermediate impurity YKYZ-C-GF-3, and preparation method and control method thereof | 江苏天士力帝益药业有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-114736171-A | Preparation method of gefitinib intermediate | 北京济美堂医药研究有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-119912397-A | Gefitinib intermediate impurity YKYZ-C-GF-3, and preparation method and control method thereof | 江苏天士力帝益药业有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119912397-A | Gefitinib intermediate impurity YKYZ-C-GF-3, and preparation method and control method thereof | 江苏天士力帝益药业有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119912397-A | Gefitinib intermediate impurity YKYZ-C-GF-3, and preparation method and control method thereof | 江苏天士力帝益药业有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119504436-A | Improved preparation method of gemfibrozil intermediate | 山东精进药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117069787-A | EGFR proteolytic targeting chimeric, preparation method, pharmaceutical composition and application thereof | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2023-11-17 | — | — | CN | disclosed |
| CN-111035619-B | Gefitinib tablet and preparation method thereof | 四川科伦药物研究院有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-109721552-B | Preparation method of gefitinib | 上海北卡医药技术有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-109721551-B | Preparation method of 3, 4-dihydro-7-methoxy-4-oxoquinazolin-6-ol acetate | 上海北卡医药技术有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114736171-A | Preparation method of gefitinib intermediate | 北京济美堂医药研究有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114736171-A | Preparation method of gefitinib intermediate | 北京济美堂医药研究有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114736171-A | Preparation method of gefitinib intermediate | 北京济美堂医药研究有限公司 | 2022-07-12 | — | — | CN | disclosed |